VISTA inhibitors in cancer immunotherapy: a short perspective on recent progresses
C Wu, X Cao, X Zhang - RSC Medicinal Chemistry, 2021 - pubs.rsc.org
V-domain immunoglobulin (Ig) suppressor of T cell activation (VISTA) is a novel negative
checkpoint regulator that mediates T cell proliferation and cytokine production. The VISTA …
checkpoint regulator that mediates T cell proliferation and cytokine production. The VISTA …
[HTML][HTML] Biomarkers for Salvage Therapy in Testicular Germ Cell Tumors
The outcome of metastatic testicular germ cell tumor patients has been dramatically
improved by cisplatin-based chemotherapy combinations. However, up to 30% of patients …
improved by cisplatin-based chemotherapy combinations. However, up to 30% of patients …
[HTML][HTML] Immune checkpoint receptor VISTA on immune cells is associated with expression of T-cell exhaustion marker TOX and worse prognosis in renal cell …
Purpose The study aimed to determine the expression of VISTA and TOX within venous
tumor thrombus and primary clear cell renal cell carcinoma (ccRCC) and to assess their …
tumor thrombus and primary clear cell renal cell carcinoma (ccRCC) and to assess their …
[HTML][HTML] High PD-L1 expression on tumor cells indicates worse overall survival in advanced oral squamous cell carcinomas of the tongue and the floor of the mouth …
ŁJ Adamski, A Starzyńska, P Adamska, M Kunc… - Biomedicines, 2021 - mdpi.com
The markers of the tumor microenvironment (TME) are promising prognostic and predictive
factors in oral squamous cell carcinoma (OSCC). The current study aims to analyze the …
factors in oral squamous cell carcinoma (OSCC). The current study aims to analyze the …
[HTML][HTML] Immune Checkpoint Inhibitors and Chimeric Antigen Receptor (CAR)-T Cell Therapy: Potential Treatment Options against Testicular Germ Cell Tumors
G Schepisi, C Gianni, MC Cursano, V Gallà… - Frontiers in …, 2023 - frontiersin.org
Germ cell tumors (GCTs) represent a heterogeneous neoplasm family affecting gonads and
rarely occurring in extragonadal areas. Most of patients have a good prognosis, often even …
rarely occurring in extragonadal areas. Most of patients have a good prognosis, often even …
[HTML][HTML] Tumor budding is an independent prognostic factor in pancreatic adenocarcinoma and it positively correlates with PD-L1 expression on tumor cells
Pancreatic adenocarcinoma is one of the leading causes of cancer-related death in
developed countries. Only 15% of patients are candidates for radical surgery, and adequate …
developed countries. Only 15% of patients are candidates for radical surgery, and adequate …
[HTML][HTML] Prognostic Significance of Systemic Inflammation Markers in Testicular and Penile Cancer: A Narrative Review of Current Literature
In contemporary clinical practice, biomarkers are indispensable in the assessment and
management of oncological patients. Although established serum tumor markers (beta …
management of oncological patients. Although established serum tumor markers (beta …
[HTML][HTML] The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors
K Evmorfopoulos, K Marsitopoulos, R Karachalios… - Cancers, 2024 - mdpi.com
Simple Summary One-fifth of patients with advanced testicular germ cell tumors (TGCTs)
develop platinum-refractory disease. Recent advances in the use of immunotherapy in solid …
develop platinum-refractory disease. Recent advances in the use of immunotherapy in solid …
[HTML][HTML] Comprehensive assessment of selected immune cell subpopulations changes in chemotherapy-naive germ cell tumor patients
K Kalavska, Z Sestakova, A Mlcakova… - Frontiers in …, 2022 - frontiersin.org
The pattern of immune cell distribution in testicular germ cell tumors (GCT) significantly
differs from the immune environment in normal testicular tissues. The present study aimed to …
differs from the immune environment in normal testicular tissues. The present study aimed to …
[HTML][HTML] IGSF11 and VISTA: a pair of promising immune checkpoints in tumor immunotherapy
XY Tang, YL Xiong, XG Shi, YB Zhao, AP Shi… - Biomarker …, 2022 - Springer
Immunotherapy has become the major treatment for tumors in clinical practice, but some
intractable problems such as the low response rate and high rates of immune-related …
intractable problems such as the low response rate and high rates of immune-related …